Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-01-22
2010-12-28
Yu, Misook (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C424S198100
Reexamination Certificate
active
07858332
ABSTRACT:
The present invention is directed to intrauterine devices that release progestins or an inflammatory cytokine after placement. These devices can be used to reduce the risk of a woman developing endometrial cancer. The invention is also directed to therapeutic methods in which a sample of uterine cells obtained from a woman is assayed to determine the extent to which PTEN null clones (latent endometrial precancers) are present. In cases where the number of such null clones is high, the woman is administered an intrauterine device that releases either a progestin or an inflammatory cytokine.
REFERENCES:
patent: 3935860 (1976-02-01), Hoff
patent: 3993057 (1976-11-01), Ramwell
patent: 4014987 (1977-03-01), Heller
patent: 4016251 (1977-04-01), Higuchi
patent: 4188951 (1980-02-01), Higuchi
patent: 4344431 (1982-08-01), Yolles
patent: 4431548 (1984-02-01), Lipowski
patent: 4578076 (1986-03-01), Luukkainen
patent: 5626148 (1997-05-01), Lehtinen
patent: 6482407 (2002-11-01), Soo Hoo
patent: 6649259 (2003-11-01), Hu
patent: 6649359 (2003-11-01), Mutter
Kim et al. (Cancer, vol. 79(2), pp. 320-327, 1997).
International Search Report for PCT/US 2007/01749 filed Jan. 23, 2007.
Written Opinion of the International Searching Authority for PCT/US 2007/01749 filed Jan. 23, 2007.
Apgar, et al., “Using Progestins in Clinical Practice,”American Family Physician62:1839-1849 (Oct. 2000).
Baak, et al., “EIN and WH094: Considering the Classification of Endometrial Hyperplasia,”J. Clin. Pathol. 58:1-6 (2005).
Benshushan, et al., “IUD Use and the Risk of Endometrial Cancer,”Eur. J. Obstet. Gynecol. Reprod. Biol.105(2):166-169 (2002).
Hecht, et al., “Prediction of Endometrial Carcinoma by Subjective Endometrial Intraepithelial Neoplasia Diagnosis,”Mod. Pathol.18:324-330 (2005).
Hill, et al., “Endometrial Cancer in Relation to Intra-Uterine Device Use,”Int. J. Cancer70:278-281 (1997).
Montz, et al., “Intrauterine Progesterone Treatment of Early Endometrial Cancer,”Am. J. Obstet. Gynecol.186(4):651-657 (Apr. 2002).
Mutter, et al., “Altered PTEN Expression as a Diagnostic Marker for the Earliest Endometrial Precancers,” J.Natl. Cancer Inst.92(1l):924-930 (Jun. 2000).
Mutter, et al., “Molecular Identification of Latent Precancers in Histologically Normal Endometrium,”Cancer Res.61:4311-4314 (Jun. 2001).
Mutter, et al., “PTEN, a Protean Tumor Suppressor,”Am. J. Pathol.158(6):1895-1898 (Jun. 2001).
Mutter, et al., “Endometrial Precancer Diagnosis by Histopathology, Clonal Analysis, and Computerized Morphometry,”J. Pathol.190:462-469 (2000).
Mutter, et al., “Changes in Endometrial PTEN Expression Throughout the Human Menstrual Cycle,”J. Clin. Endocrinol. Metab.85:2334-2338 (2000).
Perino, et al., “Treatment of Endometrial Hyperplasia with Levonorgestrel Releasing Intrauterine Devices,”Acta. Eur. Fertil.18:137-140 (1987).
Rossouw, et al., “Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women,”JAMA288:321-333 (Jul. 2002).
Seppanen, Marjo, “Cytokines and Gynecological Cancer: In Vitro Effects on Ovarian, Endometrial and Vulvar Carcinoma Cells,”Acta Universitatis Tamperensis762 (Aug. 11, 2000).
Stambolic et al., “High Incidence of Breast and Endometrial Neoplasia Resembling Human Cowden Syndrome in pten +/− Mice,”Cancer Res.60:3605-3611 (Jul. 2000).
Vereide, et al., “Nuclear Morphometric Changes and Therapy Monitoring in Patients with Endometrial Hyperplasia: a Study Comparing Effects of Intrauterine Levonorgestrel and Systemic Medroxyprogesterone,”Gynecologic Oncology91:526-533 (2003).
Zheng, et al., “Involution of PTEN-Null Endometrial Glands with Progestin Therapy,”Gynecologic Oncology92:1008-1013 (2004).
International Preliminary Report on Patentability for PCT/US 2007/01749 filed Jan. 23, 2007.
Mutter George
Viswanathan Akila
Ørbo Anne
Law Office of: Michael A. Sanzo, LLC
Natarajan Meera
The Brigham and Women's Hospital, Inc.
University of Tromsø
Yu Misook
LandOfFree
Chemoprevention of endometrial cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chemoprevention of endometrial cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemoprevention of endometrial cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4210250